Abivax SA Valuation
| ABVX Stock | EUR 7.95 0.26 3.38% |
At this time, the firm appears to be overvalued. Abivax SA shows a prevailing Real Value of €7.24 per share. The current price of the firm is €7.95. Our model approximates the value of Abivax SA from analyzing the firm fundamentals such as Return On Equity of -12.86, operating margin of 4.66 %, and Shares Outstanding of 42.32 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Abivax SA's price fluctuation is somewhat reliable at this time. Calculation of the real value of Abivax SA is based on 3 months time horizon. Increasing Abivax SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Abivax SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Abivax Stock. However, Abivax SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.95 | Real 7.24 | Hype 7.95 | Naive 8.02 |
The real value of Abivax Stock, also known as its intrinsic value, is the underlying worth of Abivax SA Company, which is reflected in its stock price. It is based on Abivax SA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Abivax SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Abivax SA helps investors to forecast how Abivax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Abivax SA more accurately as focusing exclusively on Abivax SA's fundamentals will not take into account other important factors: Abivax SA Total Value Analysis
Abivax SA is presently forecasted to have takeover price of 157.22 M with market capitalization of 277.58 M, debt of 53.45 M, and cash on hands of 6 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Abivax SA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
157.22 M | 277.58 M | 53.45 M | 6 K |
Abivax SA Investor Information
About 30.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.37. Abivax SA had not issued any dividends in recent years. Based on the key measurements obtained from Abivax SA's financial statements, Abivax SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Abivax SA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abivax SA has an asset utilization ratio of 0.0335 percent. This suggests that the Company is making €3.35E-4 for each dollar of assets. An increasing asset utilization means that Abivax SA is more efficient with each dollar of assets it utilizes for everyday operations.Abivax SA Ownership Allocation
Abivax SA holds a total of 42.32 Million outstanding shares. 30% of Abivax SA outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Abivax SA Profitability Analysis
The company reported the revenue of 37 K. Net Loss for the year was (41.36 M) with loss before overhead, payroll, taxes, and interest of (45.52 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Abivax SA's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Abivax SA and how it compares across the competition.
About Abivax SA Valuation
The stock valuation mechanism determines Abivax SA's current worth on a weekly basis. Our valuation model uses a comparative analysis of Abivax SA. We calculate exposure to Abivax SA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Abivax SA's related companies.ABIVAX Socit Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. The company was incorporated in 2013 and is headquartered in Paris, France. ABIVAX is traded on Paris Stock Exchange in France.
8 Steps to conduct Abivax SA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Abivax SA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Abivax SA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Abivax SA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Abivax SA's revenue streams: Identify Abivax SA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Abivax SA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Abivax SA's growth potential: Evaluate Abivax SA's management, business model, and growth potential.
- Determine Abivax SA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Abivax SA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Abivax Stock analysis
When running Abivax SA's price analysis, check to measure Abivax SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abivax SA is operating at the current time. Most of Abivax SA's value examination focuses on studying past and present price action to predict the probability of Abivax SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abivax SA's price. Additionally, you may evaluate how the addition of Abivax SA to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |